Impaired pupillary sensitivity in diabetic patients and correlation with visual outcome in cataract surgery Authors: Ye Li, Yuqi Xu, Qi Ren, Zeyu Pan, Fan Shi, Pengxia Wan Published: 2026 ABSTRACT PurposeTo investigate the relationship between pupillary response and diabetic characteristics in cataract patients and explore whether impaired pupillary function may impact cataract surgical outcomes and visual recovery in diabetic patients.MethodsThis prospective study included 362 participants (133 diabetic patients and 229 controls) who underwent cataract surgery. Diabetic patients were stratified by disease duration (≤ 1 year, 1–10 years, > 10 years). Pupil parameters and Visual quality metrics including higher-order aberrations (HOA), Strehl ratio (SR), and area ratio (AR) were evaluated using the OPD-Scan III aberrometer preoperatively and at 1 day, 1 week, and 1 month postoperatively.ResultsScotopic pupil diameter (PD) demonstrated a progressive decline with increasing diabetes duration. Patients with duration > 10 years showed significantly smaller scotopic pupils compared to controls (p < 0.0001) and shorter-duration subgroups (p < 0.01). PD difference deteriorated progressively in patients with duration > 1 year (p < 0.0001). Linear regression revealed that each 1% increase in HbA1c was associated with a 0.10 mm decrease in PD difference (β=-0.103, p < 0.001) and reduced scotopic PD (β=-0.112, p = 0.025). Postoperative visual quality parameters (HOA, SR, AR) showed comparable improvement between diabetic and control groups at all time points (p > 0.05), with diabetes duration showing minimal influence on outcomes.ConclusionDiabetic patients exhibit reduced pupillary sensitivity, particularly affecting scotopic pupil dilation, significantly associated with elevated HbA1c levels and longer diabetes duration. Postoperative improvements in visual quality of diabetic patients are comparable to those of non-diabetic patients, supporting use of functional intraocular lenses. Introduction As one of the most severe global chronic diseases, diabetes mellitus (DM) exhibits escalating prevalence worldwide [1, 2]. Clinically, pupillary alterations serve as critical biomarkers for neurological abnormalities including intoxications, traumatic brain injuries, and Horner’s syndrome, while emerging evidence suggests their potential in evaluating the severity of autonomic nerve damage severity across systemic disorders [3, 4]. Notably, clinical research has consistently demonstrated characteristic pupillary dysfunction in diabetes mellitus, primarily attributed to autonomic neuropathy [5]. The pupillary light reflex is modulated through the sophisticated coordination of the autonomic nervous system. Sympathetic activation induces mydriasis via norepinephrine-mediated stimulation of the pupil dilatator muscles under scotopic conditions, while parasympathetic stimulation triggers miosis through acetylcholine-dependent constriction of the pupillary sphincter muscles in photopic environments. For diabetic patients with cataracts, studies have demonstrated that advancements in preoperative management (e.g., optimized glycemic and hypertensive control), surgical techniques (e.g., improved phacoemulsification protocols), and postoperative care have significantly reduced the incidence of complications such as endophthalmitis, corneal decompensation, macular edema, and posterior capsular opacification [6]. Consequently, postoperative visual recovery in these patients is now comparable to that of non-diabetic controls [7]. However, clinical observations consistently reveal distinctive pupillary abnormalities in diabetic cataract patients, including larger baseline pupillary diameter, sluggish light reflex, and diminished responsiveness to mydriatic agents. Furthermore, long-term follow-up (> 12 months) of these patients postoperatively demonstrates a paradoxical outcome: despite achieving anatomically successful surgical results (e.g., clear corneal incisions, well-centered intraocular lenses), a subset of diabetic patients exhibits suboptimal visual acuity outcomes (e.g., best-corrected visual acuity ≤ 20/40) and suboptimal visual quality outcomes (e.g., reduced contrast sensitivity), even in the absence of overt structural abnormalities. The primary aim of this study is to elucidate the intricate relationship between pupillary light reflex and diabetic characteristic parameters in cataract patients with concomitant diabetes mellitus. Furthermore, we seek to explore whether compromised pupillary function potentially arising from diabetic autonomic neuropathy or microvascular dysregulation may underlie the observed disparities between surgical procedural success and functional visual recovery in this specific patient cohort. Subjects and methods Study subjects This prospective clinical study has been approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (File Number: 2025ER75) The study was conducted in accordance with the terms of the Declaration of Helsinki. Written informed consent was obtained from all participants before data collection. The study enrolled 362 participants undergoing phacoemulsification and intraocular lens (IOL) implantation aged between 18 and 80 years. Participants were divided into a DM (with non-proliferative diabetic retinopathy, NPDR) group (n = 133), and a non-diabetic Control group (n = 229) at the ophthalmology department in the First Affiliated Hospital of Sun-yat-sen University from October 2022 to June 2023. Exclusion criteria were as follows: (1) ocular or neurological conditions that could interfere with normal pupillary function (e.g., glaucoma, Parkinson’s disease); (2) regular use of prescription or recreational drugs that could interfere with normal pupillary function; (3) signs of iris or pupil abnormalities, or a relative afferent pupillary defect on examination, (4) pathology of optic disc and retinal disease other than diabetic retinopathy, corneal or vitreous opacity. All patients underwent the same surgical technique and received the same type of IOL (AcrySof IQ Vivity DFT015; Alcon Laboratories, Inc., USA) and same medication. Demographics, fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) levels were recorded. All patients underwent a series of ophthalmic examinations that included the following: Best-corrected visual acuity, fundus examination, chromatic pupillometry and visual quality metrics. One experienced ophthalmologist who was blinded to the study design performed measurements following standardized protocols. Ophthalmologic examination All patients underwent comprehensive ophthalmic examinations, including retinal nerve fiber layer (RNFL) thickness measurement via Optical Coherence Tomography (Topcon, TRC-50EX, Japan), slit-lamp examination, fundus examination, measurement of Best-corrected visual acuity. The examinations by OPD Scan III aberrometer (NIDEK Co. Ltd., Gamagori, Japan) was performed in a dark room. Pupil parameters were assessed under two standardized illumination conditions: photopic (85 cd/m²) and scotopic (0.05 cd/m²). All wavefront aberrometry measurements were performed under standardized mesopic (low-light) conditions with an illumination level of 0.05 cd/m² and a fixed pupil diameter of 4.0 mm using the OPD Scan III aberrometer (NIDEK Co. Ltd., Gamagori, Japan). Pupil sensitivity was defined as the difference between scotopic and photopic diameters (PD Difference). Visual quality metrics, including HOA, Strehl Ratio (SR), and Area Ratio (AR), were evaluated pre-operatively and at 1 day, 1 week, and 1 month post-operatively. Statistical methods Statistical analyses were performed using R (version 4.5, R Core Team, Vienna, Austria). Continuous variables were presented as mean ± SD or median (interquartile range), and categorical variables as frequencies (%). For parametric analyses, normality was assessed using the Shapiro–Wilk test (and Q–Q plots), and variance homogeneity was evaluated with Levene’s test. Baseline characteristics were compared using Pearson’s Chi-squared test, Fisher’s exact test, or Welch Two Sample t-test as appropriate. Subgroup comparisons of pupil parameters were conducted using independent-samples t-tests (Welch’s t-test when variances were unequal). Multiple comparisons across pupil subgroups were adjusted using Bonferroni correction. Linear regression was used to assess the association between HbA1c and pupil metrics. The impact of diabetes duration on visual quality was evaluated using one-way analysis of means. A p-value of < 0.05 was considered statistically significant. Results Sample characteristics Table 1 presents the baseline demographic and clinical characteristics of the enrolled participants. In total, 362 subjects were included (DM with non-proliferative diabetic retinopathy, n = 133; non-DM, n = 229). Sex distribution and age were comparable between groups (both p > 0.05). As expected, the DM group had significantly higher FPG and HbA1c than the non-DM group (both p < 0.001). Overall RNFL thickness did not differ significantly between the DM group and the non-DM group; The statistically significant reductions in RNFL thickness were observed in the nasal superior (100 ± 26 μm vs. 113 ± 28 μm, p = 0.008) and nasal sectors (62 ± 25 μm vs. 71 ± 16 μm, p = 0.010), which aligns with accumulating evidence of subclinical retinal nerve fiber layer loss in diabetes mellitus, even in the absence of overt diabetic retinopathy. Photopic pupil diameter was similar between groups, whereas the DM group demonstrated a larger scotopic pupil diameter and a greater photopic–scotopic PD difference (both p < 0.001). All DM participants had NPDR. The diabetic group exhibited a slightly lower postoperative best-corrected visual acuity compared to the control group (p < 0.05). Long-term follow-up reveals suboptimal visual outcomes in some patients without overt structural abnormalitie, suggesting pre-existing retinal microvascular damage could independently affect visual recovery even after successful cataract surgery. Table 1Characteristics of the subjects included in the studyCharacteristicOverallN = 3621DMN = 1331non-DMN = 2291p-value2Gender0.12 Male158 (44%)51 (38%)107 (47%) Female204 (56%)82 (62%)122 (53%)Age, year68 ± 1268 ± 1368 ± 110.9FPG, mmol/L5.55 ± 2.226.30 ± 2.544.90 ± 1.32< 0.001HbA1c, %7.20 ± 1.427.50 ± 1.325.90 ± 0.76< 0.001Pre-op BCVA, logMAR0.69 ± 0.300.67 ± 0.270.70 ± 0.310.31Post-op BCVA, logMAR0.12 ± 0.150.15 ± 0.150.10 ± 0.140.009RNFL, um101 ± 18102 ± 1699 ± 220.4 T78 ± 2278 ± 2879 ± 150.5 TS140 ± 32139 ± 37142 ± 280.057 NS108 ± 28100 ± 26113 ± 280.008 N68 ± 2062 ± 2571 ± 160.010 NI114 ± 33109 ± 30115 ± 350.6 TI151 ± 36155 ± 37148 ± 360.2Photopic PD, mm3.46 ± 0.623.50 ± 0.583.38 ± 0.690.10Scotopic PD, mm4.59 ± 0.854.74 ± 0.794.31 ± 0.90< 0.001PD Difference, mm1.13 ± 0.491.24 ± 0.480.93 ± 0.44< 0.0011n (%); Mean ± SD2Pearson’s Chi-squared test; Welch Two Sample t-test; Fisher’s exact testAbbreviations: DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; RNFL, retinal nerve fiber layer; T, temporal; N, nasal; S, superior; I, inferior, PD, pupil diameterCombinations of letters indicate sectors (e.g., TS, temporal superior; NI, nasal inferior) Table 1Characteristics of the subjects included in the studyCharacteristicOverallN = 3621DMN = 1331non-DMN = 2291p-value2Gender0.12 Male158 (44%)51 (38%)107 (47%) Female204 (56%)82 (62%)122 (53%)Age, year68 ± 1268 ± 1368 ± 110.9FPG, mmol/L5.55 ± 2.226.30 ± 2.544.90 ± 1.32< 0.001HbA1c, %7.20 ± 1.427.50 ± 1.325.90 ± 0.76< 0.001Pre-op BCVA, logMAR0.69 ± 0.300.67 ± 0.270.70 ± 0.310.31Post-op BCVA, logMAR0.12 ± 0.150.15 ± 0.150.10 ± 0.140.009RNFL, um101 ± 18102 ± 1699 ± 220.4 T78 ± 2278 ± 2879 ± 150.5 TS140 ± 32139 ± 37142 ± 280.057 NS108 ± 28100 ± 26113 ± 280.008 N68 ± 2062 ± 2571 ± 160.010 NI114 ± 33109 ± 30115 ± 350.6 TI151 ± 36155 ± 37148 ± 360.2Photopic PD, mm3.46 ± 0.623.50 ± 0.583.38 ± 0.690.10Scotopic PD, mm4.59 ± 0.854.74 ± 0.794.31 ± 0.90< 0.001PD Difference, mm1.13 ± 0.491.24 ± 0.480.93 ± 0.44< 0.0011n (%); Mean ± SD2Pearson’s Chi-squared test; Welch Two Sample t-test; Fisher’s exact testAbbreviations: DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; RNFL, retinal nerve fiber layer; T, temporal; N, nasal; S, superior; I, inferior, PD, pupil diameterCombinations of letters indicate sectors (e.g., TS, temporal superior; NI, nasal inferior) Characteristics of the subjects included in the study 1n (%); Mean ± SD 2Pearson’s Chi-squared test; Welch Two Sample t-test; Fisher’s exact test Abbreviations: DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; RNFL, retinal nerve fiber layer; T, temporal; N, nasal; S, superior; I, inferior, PD, pupil diameterCombinations of letters indicate sectors (e.g., TS, temporal superior; NI, nasal inferior) Reduced pupil sensitivity is associated with long duration of diabetes The impact of varying diabetes durations on pupil parameters was evaluated using t-tests with Bonferroni correction for multiple comparisons. Figure 1 illustrates the comparison of photopic pupil diameter (Fig. 1A), scotopic pupil diameter (Fig. 1B), and the difference between photopic and scotopic PDs (PD difference, Fig. 1C) among the control group and diabetes patients stratified by disease duration (≤ 1 year, 1 year < duration ≤ 10 years, and duration > 10 years). Fig. 1Comparison of pupil sensitivity between DM and Control Group. Each boxplot represents the median and interquartile ranges of the respective groups, with individual data points shown as dots. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns p > 0.05 Comparison of pupil sensitivity between DM and Control Group. Each boxplot represents the median and interquartile ranges of the respective groups, with individual data points shown as dots. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns p > 0.05 For photopic PD (Fig. 1A), no significant differences were observed between the control group and any of the diabetes subgroups, nor between the diabetes subgroups themselves (p > 0.05), with the sole exception of a significant difference between the control group and the duration > 10 years group (p < 0.05). In contrast, scotopic PD (Fig. 1B) showed a clear declining trend associated with disease duration. While patients with a duration of ≤ 1 year showed no significant difference compared to controls (p > 0.05), those with durations between 1 and 10 years (p < 0.01) and > 10 years (p < 0.001) exhibited significantly smaller scotopic pupil diameters than the control group. Furthermore, the duration > 10 years group showed significantly reduced scotopic PD compared to both the ≤ 1 year subgroup (p < 0.01) and the 1–10 years subgroup (p < 0.01). Consequently, the PD difference (Fig. 1C), representing pupil sensitivity, exhibited a progressive deterioration. Patients with a diabetes duration of ≤ 1 year showed no statistically significant difference compared to controls (p > 0.05). However, a significant decline was observed in patients with a duration between 1 and 10 years (p < 0.001) and > 10 years (p < 0.001) compared to controls. Notably, the decline was progressive: the 1–10 years group was significantly lower than the ≤ 1 year group (p < 0.05), and the > 10 years group demonstrated a significantly further reduction compared to the 1–10 years group (p < 0.01). Association between HbA1c levels and pupil parameters Linear regression analysis was performed to evaluate the influence of HbA1c on pupil metrics. The results demonstrated a significant negative association between HbA1c levels and the PD difference. specifically, for every 1% increase in HbA1c, the PD difference decreased by approximately 0.10 mm (β = −0.103, SE = 0.025, p < 0.001). Similarly, a significant negative correlation was observed for scotopic pupil diameter, where higher HbA1c levels were associated with a smaller pupil size in scotopic conditions (β = −0.112, SE = 0.050, p = 0.025). In contrast, no statistically significant association was found between HbA1c levels and photopic pupil diameter (β = −0.009, p = 0.814) (Table 2). These findings suggest that poorer glycemic control primarily affects pupillary dilation in darkness and overall pupil reactivity, rather than constriction under photopic conditions. Table 2Linear regression analysis of the association between HbA1c levels and pupil parametersDependent VariableCoefficient (β)Std. Errort-valuep-valuePD Difference (mm)-0.1030.025-4.112< 0.001Scotopic PD (mm)-0.1120.050-2.2560.025Photopic PD (mm)-0.0090.038-0.2360.814Note: PD, pupil diameter; HbA1c, glycated hemoglobin; SE, standard error Table 2Linear regression analysis of the association between HbA1c levels and pupil parametersDependent VariableCoefficient (β)Std. Errort-valuep-valuePD Difference (mm)-0.1030.025-4.112< 0.001Scotopic PD (mm)-0.1120.050-2.2560.025Photopic PD (mm)-0.0090.038-0.2360.814Note: PD, pupil diameter; HbA1c, glycated hemoglobin; SE, standard error Linear regression analysis of the association between HbA1c levels and pupil parameters Note: PD, pupil diameter; HbA1c, glycated hemoglobin; SE, standard error Impact of diabetes on visual quality parameters We evaluated visual quality changes in patients with DM before and after surgery (Fig. 2). Fig. 2Changes in visual quality parameters in patients with DM before and after surgery. higher-order aberrations (HOA), Strehl ratio (SR), and area ratio (AR) Changes in visual quality parameters in patients with DM before and after surgery. higher-order aberrations (HOA), Strehl ratio (SR), and area ratio (AR) Higher-Order Aberrations (HOA): Total HOA values remained relatively stable immediately on day 1 post-operation compared to baseline but showed a notable decrease at 1 week and 1 month post-operation in both groups. Contrary to the assumption that diabetes might impede visual quality recovery, the DM group did not consistently exhibit higher HOA values; in fact, while the DM group had numerically higher HOA at 1 day post-op (0.53 vs. 0.48), they showed numerically lower values at 1 week (0.25 vs. 0.30) and 1 month (0.29 vs. 0.32). However, t-test analysis confirmed that these differences were not statistically significant at any time point (p > 0.05). Strehl Ratio (SR) & Area Ratio (AR): The Strehl ratio (SR) improved markedly from negligible pre-operative levels to approximately 0.08 in the Control group and 0.05 in the DM group on the first day after surgery, followed by stabilization, with no significant differences between the groups (p > 0.05). Similarly, the area under the MTF curve (AR) demonstrated a continuous improvement from pre-operation to 1-month post-operation for both groups (Control: 20 to 44; DM: 19 to 44). Consistent with other parameters, no significant differences in AR values were observed between the two groups at any assessment time. One-way analysis of means was conducted to evaluate whether the duration of diabetes (≤ 1 year, 1–10 years, and > 10 years) influenced visual quality outcomes (HOA, SR, and AR) before and after surgery (Table 3). Table 3Comparison of visual quality parameters among diabetes patients stratified by disease durationCharacteristiccourse ≤ 1 yearN = 2211 year < course ≤ 10 yearN = 681course > 10 yearN = 431p-value2HOA pre0.46 ± 0.190.52 ± 0.340.52 ± 0.390.9HOA post 1d0.55 ± 0.220.61 ± 0.290.62 ± 0.480.9HOA post 1w0.26 ± 0.190.32 ± 0.170.29 ± 0.170.5HOA post 1 m0.28 ± 0.150.28 ± 0.130.35 ± 0.150.2SR pre0.005 ± 0.0050.015 ± 0.0160.014 ± 0.0260.2SR post 1d0.04 ± 0.020.08 ± 0.040.07 ± 0.050.011SR post 1w0.07 ± 0.030.08 ± 0.040.08 ± 0.050.5SR post 1 m0.07 ± 0.040.06 ± 0.040.05 ± 0.030.6AR pre19 ± 723 ± 818 ± 50.075AR post 1d34 ± 1440 ± 1439 ± 120.4AR post 1w37 ± 1236 ± 1138 ± 100.7AR post 1 m38 ± 1147 ± 1245 ± 150.131Mean ± SD2One-way analysis of means Table 3Comparison of visual quality parameters among diabetes patients stratified by disease durationCharacteristiccourse ≤ 1 yearN = 2211 year < course ≤ 10 yearN = 681course > 10 yearN = 431p-value2HOA pre0.46 ± 0.190.52 ± 0.340.52 ± 0.390.9HOA post 1d0.55 ± 0.220.61 ± 0.290.62 ± 0.480.9HOA post 1w0.26 ± 0.190.32 ± 0.170.29 ± 0.170.5HOA post 1 m0.28 ± 0.150.28 ± 0.130.35 ± 0.150.2SR pre0.005 ± 0.0050.015 ± 0.0160.014 ± 0.0260.2SR post 1d0.04 ± 0.020.08 ± 0.040.07 ± 0.050.011SR post 1w0.07 ± 0.030.08 ± 0.040.08 ± 0.050.5SR post 1 m0.07 ± 0.040.06 ± 0.040.05 ± 0.030.6AR pre19 ± 723 ± 818 ± 50.075AR post 1d34 ± 1440 ± 1439 ± 120.4AR post 1w37 ± 1236 ± 1138 ± 100.7AR post 1 m38 ± 1147 ± 1245 ± 150.131Mean ± SD2One-way analysis of means Comparison of visual quality parameters among diabetes patients stratified by disease duration 1Mean ± SD 2One-way analysis of means Generally, the duration of diabetes did not show a significant impact on most visual quality metrics throughout the observation period. For Higher-Order Aberrations (HOA), no statistically significant differences were found among the three duration groups at any time point (Pre-op: p = 0.9; Post-1d: p = 0.9; Post-1w: p = 0.5; Post-1 m: p = 0.2). Similarly, the Area Ratio (AR) showed comparable improvements across all groups without significant inter-group differences (Pre-op: p = 0.075; Post-1 m: p = 0.13). Regarding the Strehl Ratio (SR), a statistically significant difference was observed on the first day after surgery (SR post 1d, p = 0.011). Specifically, patients with a duration of 1–10 years (median: 0.06) and > 10 years (median: 0.05) exhibited slightly higher SR values compared to those with a duration of ≤ 1 year (median: 0.03). However, this difference was transient; no significant differences in SR were detected at 1 week (p = 0.5) or 1 month (p = 0.6) post-operation, suggesting that long-term visual recovery in terms of Strehl ratio is not significantly compromised by the duration of diabetes. Discussion Diabetes mellitus induces small nerve fiber damage, manifesting as reduced pupillary sensitivity linked to neural regulation impairment [8]. Pupillary light reflex impairment occurs early in diabetic patients, preceding the appearance of overt clinical symptoms [9–10]. Our findings demonstrate a significant correlation between reduced pupillary sensitivity and elevated HbA1c levels, indicating that poorer glycemic control is associated with more severe impairment of pupillary regulatory function, which aligns with previous studies reporting diabetic pupillary reflex abnormalities [11–12].Longitudinal analysis showed progressive pupillary sensitivity decline with diabetes duration. Patients with disease duration > 1 year exhibited greater impairment than those ≤ 1 year, with a stabilized decline rate after 10 years, suggesting a potential neurological adaptation or maximal damage threshold. Taken together, our results suggest that diabetic patients exhibit reduced pupillary sensitivity, particularly affecting scotopic pupil dilation, significantly associated with elevated HbA1c levels and longer diabetes duration. For diabetic patients with cataracts, studies have demonstrated that advancements in preoperative management (e.g., optimized glycemic and hypertensive control), surgical techniques (e.g., improved phacoemulsification protocols), and postoperative care have significantly reduced the incidence of complications such as endophthalmitis, corneal decompensation, macular edema, and posterior capsular opacification [13–15]. Consequently, postoperative visual recovery in these patients is now comparable to that of non-diabetic controls [16]. However, clinical observations consistently reveal distinctive pupillary abnormalities in diabetic cataract patients, including larger baseline pupillary diameter, sluggish light reflex, and diminished responsiveness to mydriatic agents. Furthermore, long-term follow-up (> 12 months) of these patients postoperatively demonstrates a paradoxical outcome: despite achieving anatomically successful surgical results (e.g., clear corneal incisions, well-centered intraocular lenses), a subset of diabetic patients exhibits suboptimal visual acuity outcomes and suboptimal visual quality outcomes (e.g., reduced contrast sensitivity), even in the absence of overt structural abnormalities [17–20].Recognizing the potential impact of pupillary sensitivity on low-light visual quality in diabetic cataract patients, we assessed visual outcomes one-month post-phacoemulsification and IOL implantation. Diabetic patients exhibited improvements in HOA, SR, and MTF area under low-light conditions, with no statistically significant differences compared to non-diabetic patients. However, This study has several limitations. First, visual quality assessment was limited to objective metrics (HOA, SR, AR) without evaluating functional parameters like contrast sensitivity or patient-reported outcomes, which may restrict comprehensive interpretation of real-world visual performance. the complexity of real-world visual environments necessitates continued vigilance regarding the potential long-term implications of reduced pupillary sensitivity on visual quality in diabetic retinopathy patients. Future research should focus on longitudinal assessments and more nuanced investigations of the intricate interactions between glycemic control, neural integrity, and visual function.Second, pupillometry relied on static diameter measurements without assessing dynamic parameters, potentially underestimating subtle autonomic dysfunction. Further investigation into pupillometric parameters (e.g., dynamic pupillary response, light adaptation latency) as predictors of postoperative visual outcomes is warranted. Third, the use of a single EDOF IOL may introduce pupil-dependent biases, as its optical performance could interact differently with impaired pupillary function in diabetic patients. In conclusion, DM patients demonstrated significantly reduced pupillary sensitivity compared to non-DM individuals.Moreover, one month following phacoemulsification and IOL implantation, DM patients exhibited improvements in HOA, SR, and MTF area under low-light conditions. Notably, these improvements were not statistically significantly different from non-diabetic retinopathy patients, suggesting that functional IOL remains a viable option for patients with non-proliferative diabetic retinopathy. However, it is crucial to emphasize that given the objective impact of pupillary sensitivity on visual quality and the inherent complexity of real-world visual environments, careful consideration of this factor’s potential implications for DM populations remains paramount in clinical management. Future research should continue to explore the nuanced interactions between diabetes-related physiological changes and visual function.